Isolated rat adipocytes produce prostacyclin (PGI 2 ) in relatively large quantities during norepinephrine (NE)-induced lipolysis. The endogenous NE-induced production rate of PGI 2 , calculated from the NE-induced production rate of PGI 2 observed in our studies (2.2 ng/10 6 cells/2 h) and from the number of fat cells in the normal organism, is 1.46 ng/kg/min for rats, 4.46 ng/kg/min for men, and 11.86 ng/kg/min for women. These rates are comparable to the exogenous PGI 2 infusion rate that alters platelet aggregation and blood pressure in rats and humans. Exogenous PGI 2 failed to modify the rate of NE-induced lipolysis. Inhibition of endogenous PGI 2 production by indomethacin had no effect on the rate of NE-induced lipolysis when either a maximal or submaximal lipolytic concentration of NE was used.
) is produced by endothelial cells 1 and other cells 2 and is a potent inhibitor of platelet aggregation and a potent vasodilator. However, the presence of PGI 2 in adipocytes has not previously been detected. In the studies described below, we demonstrate that isolated rat adipocytes produce PGI 2 in relatively large quantities. We present evidence that the hormone-stimulated production of PGI 2 in large quantities may be of physiologic importance.
METHODS

Isolation and incubation of adipocytes.
Adipocytes were isolated from 125-150-g male Sprague-Dawley rats by the method of Rodbell, 3 as previously used in our laboratory. 4 One-or 2-ml samples of cells were incubated in KrebsRinger phosphate buffer, with half the usual concentration of calcium and 4 g/dl of essentially fatty acid-free albumin at 37°C in a metabolic shaker. The medium was separated from the cells using a Celotate Millipore filter with a 1-/xm diameter pore size. The medium was then frozen until assayed for the arachidonic acid derivatives. Concurrently, 1-ml samples were incubated under identical conditions for determination of glycerol release and for counting of cells, as previously described. 4 Preliminary studies were done to determine the optimal concentration of cells necessary to eliminate the effects of endogenous inhibitors, 5 ' 6 and to determine the dose-response relationship between norepinephrine (NE) stimulation and lipolysis, measured as glycerol release. These studies demonstrated a linear release of glycerol when a 1% cell suspension was employed. When the suspension contained 2% or more of the cells (by volume), the release of glycerol was not linear with time. Progressively higher concentrations of cells produced progressively greater degrees of inhibition of lipolysis. Using a 1% cell suspension and a 45-min incubation, maximal lipolysis was obtained at 5 x 10~7 M NE. Submaximal lipolysis (approximately 60% of maximal) was obtained with 10~7 M NE. No lipolytic effect DIABETES, VOL. 30, FEBRUARY 1981 was produced by 10~8 M. Further studies demonstrated persistence of maximal lipolysis for at least 3 h after a single add ition of 10~5 M NE, but loss of effect with doses of 10~7 M after 1 h, consistent with the degradation of NE by adipocytes. 7 Accordingly, when cells were incubated with 10~7 M for more than 1 h, a dose of 10~7 M NE (final concentration) was added every hour. This approach yielded a linear lipolytic response, with no evidence of a cumulative or additive effect.
Consequently, all studies of the production of arachidonic acid derivatives were done in a 1% cell suspension. A dose of 10" s M NE was used to determine the maximal response to this hormone. A dose of 10~7 M NE every hour was used to produce a submaximal linear response. The use of a submaximal concentration of NE provides a sensitive assay for both lipolytic and antilipolytic effects of substances investigated in this system. Measurement of prostaglandins, prostacyclin, and thromboxane A 2 . Prostaglandin (PG) E 2 , PGF 2a , PGI 2 (measured as its stable metabolite 6-keto-PGF 1a ), and thromboxane A 2 (TXA 2 , analyzed as its stable product TXB 2 ) were measured by radioimmunoassay in the medium of the adipocyte incubations after separation from the cells by the Millipore filter, as noted above. The serologic specificities of the antisera used in the radioimmunoassays in this study have been described. 8 " 12 Studies were performed with palmitate, oleate, and linoleate in the Krebs-Ringer phosphate buffer with albumin to assess the effects of free fatty acids (FFAs) on the radioimmunoassays used in this study. Each FFA was transferred to albumin by means of Celite particles. 13 The concentration of FFAs was determined by a colorimetric method.
14 At concentrations of each FFA comparable to the theoretical maximum expected in the medium after stimulation with NE 10~5 M for 2 h, no reaction with the serologic assays for PGI 2 and PGF 2a was observed. These studies were based on the assumptions of complete hydrolysis of triglycerides, no reincorporation of FFAs into adipocyte lipids, and the following composition of the theoretical maximum concentration of total FFAs (3.6 /xEq/ml) released into the medium during hormone-stimulated lipolysis: palmitate 18%, oleate 23%, and linoleate 48%. 15 Furthermore, the addition of indomethacin resulted in complete inhibition of NE-induced production of PGI 2 and PGF 2a despite the absence of any effect of indomethacin on lipolysis (see RESULTS). In contrast, in the PGE 2 assay system, 0.59 /u.M oleate produced 45% inhibition of binding and indomethacin failed to inhibit the apparent NE-induced production of PGE 2 . In the TXB 2 assay system, 0.7 pM linoleate produced 16% inhibition of binding. For these reasons, we report the results of our studies with PGI 2 and PGF 2a . Data were analyzed using Student's two-tailed t test. Results are expressed as the mean ± SEM.
RESULTS
Production of arachidonic acid derivatives.
A maximally effective lipolytic dose of NE (10~5 M) produced a significant increase in the production of PGF 2a and PGI 2 ( Figure 1 ). The production rate of PGF 2a was 0.3 ng/10 6 cells/2 h. The production rate of PGI 2 was 2.2 ng/10 6 cells/2 h. Indomethacin, 50 fiM, produced a marked and complete inhibition jof the basal production of PGI 2 at 120 min, and of the NE produced a significant increase in the production of PGF2a (P < 0.01, NE versus basal at 120 min) and of 6-keto-PGF,Q (P < 0.05, NE versus basal at 60 min; P < 0.02, NE versus basal at 120 min). Indomethacin significantly inhibited the basal production of 6-keto-PGF,a (P < 0.05, indomethacin versus basal at 120 min) and the NE-induced production of PGF2a (P < 0.02, NE + indomethacin versus NE at 120 min) and of 6-keto-PGF1a (P < 0.01, NE + indomethacin versus NE at 60 min; P < 0.001, NE + indomethacin versus NE at 120 min).
NE-induced production of PGF 2a at 120 min, and of PGI 2 at 60 and 120 min. PGE 2 was produced at an apparent rate of 1.1 ng/10 6 cells/2 h if one assumes no cross-reaction with oleate or linoleate. Since such cross-reaction probably occurred, the true rate was probably lower. Indomethacin, 50 fxM, failed to inhibit the apparent NE-induced production of PGE 2 , consistent with a reaction of FFAs with the PGE 2 antiserum. TXA 2 (measured as TXB 2 ) was produced at an apparent rate of 0.13 ng/10 6 cells/2 h, if one assumes no cross-reaction with linoleate. Since some cross-reaction probably occurred, this indicates that the adipocytes produced little or no TXA 2 ; if any was produced, the quantity was small in comparison with the quantity of PGI 2 produced.
Similar results were obtained with a submaximal dose of NE (10~7 M) (Figure 2) . Again, there was a significant increase in the production of PGI 2 (P < 0.02, NE versus basal at 120 min). Again, indomethacin produced a complete inhibition of the NE-induced production of PGI 2 (P < 0.01, NE and indomethacin versus NE alone at 120 min). This submaximal dose of NE also stimulated production of PGF 2a ; this was fully inhibited by indomethacin (results not shown).
Indomethacin had no effect on basal lipolysis or on lipolysis induced by NE, 10~5 M or 10~7 M (Figures 1 and 2) . Effect of PGI 2 on lipolysis. PGI 2 is not antilipolytic. Concentrations as high as 10"
5 M had no effect on NE-induced lipolysis under conditions in which PGE 2 is predictably antilipolytic. 4 Because PGI 2 is unstable, our studies were performed under conditions designed to maximize the likelihood of an effect. The PGI 2 was dissolved in a carbonate buffer (pH 10) in all studies, since others have shown that this provides sufficient stability to demonstrate effects on blood pressure and platelet aggregation. Experiments were done with a 10-min as well as a 45-min incubation, and with TIME , MINUTES a 10-min preincubation; incubations were done at 25 C C as well as at 37°C. Under no circumstances did PGI 2 decrease or increase the rate of lipolysis produced by NE, 10~7 M.
Furthermore, indomethacin inhibited the production of PGI 2 induced by NE, 10" 5 M and 10" 7 M, but had no effect on the rate of lipolysis induced by these concentrations of NE, which produced a maximal and submaximal lipolytic response, respectively. This indicates that endogenous PGI 2 had no effect on lipolysis.
DISCUSSION
Our findings demonstrate that isolated rat adipocytes produce PGI 2 in relatively large quantities during NE-induced lipolysis.
The hormone-stimulated production of PGI 2 in relatively large quantities may be of great physiologic importance. Quantitatively, the adipose cell mass is a large part of the body cell mass in the normal organism and in obesity, and is widely distributed throughout the body. The adipose organ is estimated to weigh 4.8 kg in a normal man and 11.8 kg in a normal woman. 16 If one calculates the endogenous production rate of PGI 2 from adipocytes, based on the production rate of PGI 2 found in our studies and on published measurements of the total number of fat cells present in the intact organism, one finds that the endogenous production rate of PGI 2 during stimulation with NE is nearly identical to the exogenous infusion rate of PGI 2 that alters platelet aggregation and blood pressure.
For example, a 432-g nonobese Zucker rat has a total of at least 34.4 x 10 6 adipocytes in three adipose depots. 17 (To arrive at this total, the published figure for the left epididymal fat pad was taken twice; the figure for the left retroperitoneal fat pad was taken twice; and the figure for the dorsal scapular subcutaneous fat pad was taken only once.) The production rate of PGI 2 in our adipocytes under stimulation with NE 10~5 M was 2.2 ng/10 6 cells/2 h. Therefore, the production rate of PGI 2 per rat is 2.2 ng/10 6 cells/2 h x 34.4 x 10 6 cells/0.432 kg rat = 1.46 ng/kg/min. This figure certainly underestimates the number of fat cells in the rat, since cells from only three pads were measured. Nevertheless, this correlates well with the exogenous infusion rate of PGI 2 (approximately 3 ng/kg/min) that causes vasodilatation in the rat 18 and with the exogenous infusion rate (approximately 5-10 ng/kg/min) that inhibits platelet aggregation and causes vasodilatation in man. 19 Our findings indicate that the endogenous production rate of PGI 2 from the adipocyte mass during catecholamine stimulation in the absence of insulin is comparable with the exogenous infusion rate that produces biologic effects in the rat and in man. Although our measurements were made in Sprague-Dawley rats and the figures for the rat fat cell number are derived from Zucker rats, this should not alter the results, since the number of fat cells in the epididymal and retroperitoneal pads of the two strains is comparable. 20 We use figures from the studies in Zucker rats because these studies include an estimate of the subcutaneous fat pad, which is not available for the Sprague-Dawley rat.
If one makes similar calculations for normal human subjects using the production rate of PGI 2 we observed in rat fat cells and the number of fat cells present in human subjects, the results are similar. The normal 72-kg man has 17.5 x 10 9 fat cells. 16 At a PGI 2 production rate of 2.2 ng/10 cells/2 h, the production rate in normal man is 2.2 ng/10 6 cells/2 h x 17.5 x 10 9 cells/72 kg = 4.46 ng/kg/min. The normal 64-kg woman has 41.4 x 10 9 fat cells. 16 Using the same PGI 2 production rate of 2.2 ng/10 6 cells/2 h, the production rate for a normal woman is 2.2 ng/10 6 cells/2 h x 41.4 x 10 9 cells/64 kg = 11.86 ng/kg/min. These endogenous adipocyte production rates for PGI 2 in normal man and woman are virtually identical to the exogenous infusion rate of 5-10 ng/kg/min that is necessary to inhibit platelet aggregation and to affect blood pressure and heart rate in man. 19 One may predict from our findings that in circumstances of maximal catecholamine stimulation and insulin deficiency, in diabetic ketoacidosis for example, the production of PGI 2 and other arachidonic acid derivatives by adipocytes may be of such a magnitude that these substances derived from this source enter the circulation and produce biologic effects. It is also possible that PGI 2 and other arachidonic acid derivatives derived from adipocytes enter the circulation during maximal catecholamine stimulation even in the presence of normal basal insulin concentrations. Our findings do not exclude a contribution from other sources, such as endothelial cells, to the plasma PGI 2 concentration. Rather, they suggest that the adipocyte, under certain conditions, may be one of several sources of the PGI 2 in the circulation.
We propose that PGI 2 rather than PGE 2 is the substance that accounts for the functional vasodilatation that accompanies lipolysis. 21 " 23 When lipolytic substances are infused into the arterial supply of adipose tissue, they also cause an increase in the blood flow to the adipose tissue. 21 This functional dilatation is abolished by indomethacin and aspirin. 23 Although it has been proposed that the vasodilator substance is PGE 2 , 22 ' 23 we suggest that it is PGI 2 . This proposal is consistent with our observation that PGI 2 is produced in larger quantity than PGE 2 during NE-induced lipolysis, with the fact that PGI 2 is a more potent vasodilator than PGE 2 , and with the observation that no vasodilator substance could be detected in the venous effluent of the activated adipose tissue, but only from extracts of adipose tissue. 21 The last observation is consistent with the known instability of PGI 2 .
Our observations and calculations suggest that the production of PGI 2 by adipocytes is an important modulator of the regulation of vascular tone and platelet function by catecholamines. The PGI 2 released from adipose tissue may participate in the regulation of the perfusion of adipose tissue, other vascular beds, or both. It may also inhibit platelet aggregation in the vascular bed of adipose tissue, other vascular beds, or both. Adipose tissue is subject to great mechanical stress (when the organism sits or lies, for example) but lacks the mechanical protection provided to other organs by the skeleton. PGI 2 , by virtue of its ability to cause vasodilatation and inhibit platelet aggregation, may contribute in an important way to the maintenance of luminal patency in the vascular bed of adipose tissue and possibly other tissues as well.
The origin of the arachidonic acid that serves as substrate for the synthesis of PGI 2 and other prostaglandins in adipocytes is not known, but may be the adipocyte phospholipids rather than triglycerides. 24 Although arachidonic acid is a constituent of both the triglycerides and phospholipids of rat adipocytes, it represents a small fraction (1-2%) of the fatty acids derived from triglycerides, 15 ' 24 but a large fraction (18%) of the fatty acids derived from phospholipids. 24 In addition, the quantity of PGI 2 produced by the adipocytes in our study is much smaller than one would predict from the amount of arachidonic acid released during lipolysis of triglycerides, assuming that arachidonic acid constitutes 1 -2% of the fatty acids derived from triglycerides 15 ' 24 and is utilized completely for synthesis of PGI 2 and other prostaglandins. The large concentration of arachidonic acid present in the phospholipids of the adipocyte and the small yield of PGI 2 observed in comparison with the amount of arachidonic acid released during lipolysis of triglycerides suggest that the production of PGI 2 and other prostaglandins by the adipocyte does not depend on the total quantity of arachidonic acid present in the cell or medium but on the availability of arachidonic acid at a specific intracellular location, and that PGI 2 and other prostaglandins may be derived from the arachidonic acid present in large concentration in the phospholipid of the adipocyte. This arachidonic acid may be released during hormone-induced lipolysis as a consequence of the activation of a cyclic AMP-dependent phospholipase A, possibly phospholipase A 2 . 25 
